22-41176537-C-T

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2

The NM_001429.4(EP300):​c.5061+9C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0247 in 1,613,432 control chromosomes in the GnomAD database, including 650 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.021 ( 57 hom., cov: 32)
Exomes 𝑓: 0.025 ( 593 hom. )

Consequence

EP300
NM_001429.4 intron

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:5

Conservation

PhyloP100: -0.656

Publications

5 publications found
Variant links:
Genes affected
EP300 (HGNC:3373): (E1A binding protein p300) This gene encodes the adenovirus E1A-associated cellular p300 transcriptional co-activator protein. It functions as histone acetyltransferase that regulates transcription via chromatin remodeling and is important in the processes of cell proliferation and differentiation. It mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. This gene has also been identified as a co-activator of HIF1A (hypoxia-inducible factor 1 alpha), and thus plays a role in the stimulation of hypoxia-induced genes such as VEGF. Defects in this gene are a cause of Rubinstein-Taybi syndrome and may also play a role in epithelial cancer. [provided by RefSeq, Jul 2008]
EP300-AS1 (HGNC:50504): (EP300 antisense RNA 1)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.88).
BP6
Variant 22-41176537-C-T is Benign according to our data. Variant chr22-41176537-C-T is described in ClinVar as Benign. ClinVar VariationId is 158566.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population sas. GnomAd4 allele frequency = 0.0208 (3171/152180) while in subpopulation SAS AF = 0.0338 (163/4818). AF 95% confidence interval is 0.0296. There are 57 homozygotes in GnomAd4. There are 1670 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High AC in GnomAd4 at 3171 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
EP300NM_001429.4 linkc.5061+9C>T intron_variant Intron 30 of 30 ENST00000263253.9 NP_001420.2
EP300NM_001362843.2 linkc.4983+9C>T intron_variant Intron 29 of 29 NP_001349772.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
EP300ENST00000263253.9 linkc.5061+9C>T intron_variant Intron 30 of 30 1 NM_001429.4 ENSP00000263253.7

Frequencies

GnomAD3 genomes
AF:
0.0208
AC:
3169
AN:
152062
Hom.:
57
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00485
Gnomad AMI
AF:
0.0241
Gnomad AMR
AF:
0.0180
Gnomad ASJ
AF:
0.0629
Gnomad EAS
AF:
0.000193
Gnomad SAS
AF:
0.0334
Gnomad FIN
AF:
0.0560
Gnomad MID
AF:
0.0443
Gnomad NFE
AF:
0.0241
Gnomad OTH
AF:
0.0230
GnomAD2 exomes
AF:
0.0258
AC:
6445
AN:
249560
AF XY:
0.0274
show subpopulations
Gnomad AFR exome
AF:
0.00371
Gnomad AMR exome
AF:
0.0102
Gnomad ASJ exome
AF:
0.0616
Gnomad EAS exome
AF:
0.000163
Gnomad FIN exome
AF:
0.0588
Gnomad NFE exome
AF:
0.0253
Gnomad OTH exome
AF:
0.0302
GnomAD4 exome
AF:
0.0251
AC:
36731
AN:
1461252
Hom.:
593
Cov.:
31
AF XY:
0.0259
AC XY:
18819
AN XY:
726920
show subpopulations
African (AFR)
AF:
0.00436
AC:
146
AN:
33464
American (AMR)
AF:
0.0108
AC:
482
AN:
44708
Ashkenazi Jewish (ASJ)
AF:
0.0599
AC:
1564
AN:
26132
East Asian (EAS)
AF:
0.000126
AC:
5
AN:
39698
South Asian (SAS)
AF:
0.0375
AC:
3234
AN:
86220
European-Finnish (FIN)
AF:
0.0549
AC:
2934
AN:
53396
Middle Eastern (MID)
AF:
0.0534
AC:
288
AN:
5390
European-Non Finnish (NFE)
AF:
0.0238
AC:
26475
AN:
1111922
Other (OTH)
AF:
0.0266
AC:
1603
AN:
60322
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.477
Heterozygous variant carriers
0
2248
4497
6745
8994
11242
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
1006
2012
3018
4024
5030
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0208
AC:
3171
AN:
152180
Hom.:
57
Cov.:
32
AF XY:
0.0224
AC XY:
1670
AN XY:
74402
show subpopulations
African (AFR)
AF:
0.00484
AC:
201
AN:
41534
American (AMR)
AF:
0.0179
AC:
274
AN:
15278
Ashkenazi Jewish (ASJ)
AF:
0.0629
AC:
218
AN:
3468
East Asian (EAS)
AF:
0.000193
AC:
1
AN:
5168
South Asian (SAS)
AF:
0.0338
AC:
163
AN:
4818
European-Finnish (FIN)
AF:
0.0560
AC:
593
AN:
10586
Middle Eastern (MID)
AF:
0.0476
AC:
14
AN:
294
European-Non Finnish (NFE)
AF:
0.0241
AC:
1637
AN:
68012
Other (OTH)
AF:
0.0227
AC:
48
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
161
322
484
645
806
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
44
88
132
176
220
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0243
Hom.:
81
Bravo
AF:
0.0178
Asia WGS
AF:
0.0160
AC:
56
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:2
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Feb 08, 2013
Genetic Services Laboratory, University of Chicago
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

not provided Benign:2
Sep 16, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

Rubinstein-Taybi syndrome due to EP300 haploinsufficiency Benign:1
Feb 02, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.88
CADD
Benign
0.66
DANN
Benign
0.77
PhyloP100
-0.66
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs73176628; hg19: chr22-41572541; COSMIC: COSV99610297; API